Abstract B090: Defining The Immune Mechanisms Required For iRGD-guided Low Dose IL-2 Therapy in Pancreatic Ductal Adenocarcinoma
Pancreatic ductal adenocarcinoma (PCAD) remains one of the deadliest cancers with minimal treatment options, highlighting the need for more effective immunotherapeutic strategies capable of overcoming its highly immunosuppressive tumor microenvironment. Tumor penetrating peptides such as iRGD enhance the delivery and...